Labrys Biologics Raises $31M
San Francisco-based Labrys Biologics, a biopharmaceuticals firm focused on treatments for chronic migraine, said this morning that it has raised $31M in a Series A financing round. The round came from venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. As part of the deal, Labrys said it acquired RN-307, a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine, from Pfizer. Labrys is headed by Steven P. James.
posted on Thursday, January 3, 2013 (Link to more information)
Related companies:
Labrys Biologics
Related stories:
> Canaan Partners Raises $675M Fund
> Solstice Biologics Raises $18M
> Canaan Partners Adds Nina Kjellson To Boost West Coast Presence
> BioMarin Buys Plant From Pfizer
> Unchained Labs Lands $25M
silicontap.com Home